Drug Trial Radar · NCT07555054
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
Nov 11, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to evaluate the efficacy and safety of HS-10390 in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 30 and \<90 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and \< 3000 mg/g
Conditions
- Chronic Kidney Disease
Interventions
HS-10390Drug
HS-10390
HS-10390Drug
HS-10390
HS-10390Drug
HS-10390
IrbesartanDrug
Target dose of 300 mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12Time frame: Frame: From baseline (Day 1) until Week 12 (Day 85)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.